The safety of synthetic levothyroxine sodium tablets (Thyro-Tabs® Canine; LLOYD, Inc.) in dogs was evaluated in a randomized, sham-dose controlled, parallel-group study. Young, healthy, euthyroid Beagle dogs were randomized into four groups (four females and four males per group) and received single daily doses of 0×, 2× (0.044 mg/kg), This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
| INTRODUCTION
) are not expected to cause overt clinical signs in healthy dogs (DeClementi Safrit, 2001) . A case study (Hansen, 1992) in which a 16.8-kg dog ingested up to 850 0.2-mg levothyroxine tablets (maximum dose 10.12 mg/kg; actual exposure unknown due to vomiting and activated charcoal treatment) was associated with a serum total thyroxine (TT4) concentration of 4,900 nmol/L (reference range: 5.3-26.7 nmol/L) 3-9 hr after exposure. By 36 days after exposure, the TT4 serum concentration was within reference ranges. During this time, the only signs the dog had were bilateral hippus on initial examination, transient increased heart rate on days 3 and 6 after exposure, and transient increase in alanine transferase (ALT) that peaked on day 6 after exposure.
Multiple-dose studies in which levothyroxine sodium was given to euthyroid dogs used either extreme doses of 1 or 2 mg kg −1 day −1 (High, Capen, & Black, 1981a,b; Minaire, Forichon, Freminet, Cagnard, & Dallevet, 1983) or doses ranging from 1× to 5× (0.02-0.1 mg kg −1 day −1 ) the recommended starting dose for hypothyroid dogs (Heseltine et al., 2005; Le Traon, Burgaud, & Horspool, 2008; Li, Chen, Tiller, & Kunkle, 1986; Panciera, Keene, & Mier, 1992; Simpson, Devi, & Whittem, 2013; Tidholm et al., 2003; Van Vleet, Ferrans, & Badylak, 1982; Ziglioli et al., 2017) . There was a | 255
disparate effect of extreme levothyroxine dosing on body weight, with the dogs that received 1 mg kg −1 day −1 levothyroxine sodium having an 8.6% increase in mean body weight (High et al., 1981a,b) and the dogs that received 2 mg kg −1 day −1 having a mean 12% decrease in body weight (Minaire et al., 1983) . The dogs that received 1 mg kg −1 day −1 had significant increases in temperature, pulse, and respiration after 1 week of treatment. The dogs receiving 2 mg kg −1 day −1 had consistent increases in daily measurements of metabolic rate of >30% over baseline. Neither of these studies reported serum TT4 concentrations.
In the multiple-dose studies in which dogs received 1×-5× the starting dose, no behavioral signs (panting, hyperactivity, polyuria/polydypsia) of thyrotoxicosis were reported (Heseltine et al., 2005; Le Traon et al., 2008; Li et al., 1986; Panciera et al., 1992; Simpson et al., 2013; Tidholm et al., 2003; Van Vleet et al., 1982; Ziglioli et al., 2017) . The only overt clinical sign reported in any of these studies was mild weight loss (Heseltine et al., 2005) . No differences in electrocardiographic and echocardiographic findings were detected between dogs receiving approximately 0.04 mg kg −1 day −1 and untreated dogs (Panciera et al., 1992) , and there was no difference in mean survival times in dogs with congestive heart failure that received levothyroxine (0.02 mg kg −1 day −1 for 1 month, then 0.04 mg kg −1 day −1
) and those that did not (Tidholm et al., 2003) .
Among these studies, serum TT4 concentrations were within reference ranges for nadir samples (Van Vleet et al., 1982) to 2× the upper limit of the reference range for peak samples (Heseltine et al., 2005) .
One of the studies in which the hypothalamic-pituitary-thyroid (HPT) axis was evaluated did not find any difference in the serum TT4
response to thyrotropin-releasing hormone (TRH) stimulation between dogs receiving 0.4 mg levothyroxine sodium q 12 hr and untreated euthyroid dogs (Li et al., 1986) . However, the interpretability of these results is limited as the levothyroxine sodium dose was not standardized to body weight or body surface area (weight range of dogs 8-23 kg).
The HPT axis was suppressed in studies in which the levothyroxine sodium dose was standardized, as evidenced by lack of serum TT4 response to TRH stimulation or thyroid-stimulating hormone (TSH) stimulation , pituitary morphometrics consistent with suppression and thyroid morphometrics consistent with lack of TSH stimulation , and decreased endogenous serum TSH concentrations (Heseltine et al., 2005; Ziglioli et al., 2017) . The HPT axis was still partially suppressed as assessed by TSH stimulation at 4 weeks after stopping levothyroxine sodium in some dogs that were dosed at 0.5 mg/m 2 twice a day for 8 weeks . However, TSH serum concentrations were at pretreatment values at 1 week after discontinuation of dosing (mean 0.026 mg/kg q 24 hr) over a 16-week time frame that produced peak TT4 serum concentrations within a desired therapeutic range of 40-70 nmol/L (Ziglioli et al., 2017) .
Since the time that the majority of these studies were conducted, the regulatory environment for levothyroxine sodium tablets in the USA has dramatically changed. In 1997, the United States Food and Drug Administration (USFDA) mandated that all levothyroxine sodium tablet products for humans become approved drug products (Federal Register, 1997 product must meet all of the quality standards for human tablets.
These standards included the tightened potency specification and a more stringent dissolution specification than that listed in the USP. As these variables are the proximate in vitro indicators for the amount of levothyroxine available for in vivo absorption, there was the distinct possibility that LLOYD's product might act differently than formulations used in previous studies and could be more bioavailable. As such, a full Target Animal Safety study was performed in support of the Thyro-Tabs ® Canine USFDA approval.
The aim of this study was to complement and expand on the studies in the veterinary literature that evaluated the effects of repeateddose oral administration of levothyroxine sodium in dogs. Specifically, this study used a formulation manufactured to meet tighter potency and dissolution criteria than formulations used in previous studies.
It also used a dosage (0.220 mg kg −1 day −1
) that had not been previously evaluated, being between the estimated 0.1 mg kg −1 day −1 dosage not associated with overt clinical signs (Li et al., 1986 ) and the
dosage that did induce overt signs (High et al., 1981a,b) .
The objective was to investigate the safety of levothyroxine sodium, in this specific tablet formulation, given to dogs every 24 hr at dosages of 0, 0.044, 0.132, or 0.220 mg/kg for 182 days. As the recommended starting dosage, which was later established by the companion Efficacy study (Lewis, Morrow, Jacobsen, & Lloyd, 2018) 
| MATERIALS AND METHODS
The study was conducted at Kingfisher International (Stouffville, Ontario, Canada). It was in compliance with Good Laboratory Practices and site procedures and United States Food and Drug Administration
Guidelines on the conduct of target animal safety studies in effect at the time (Center for Veterinary Medicine Guidance for Industry #33).
The study was approved by the test facility's Animal Care Committee prior to commencement. 
| Animals

| Experimental design
The study comprised of four treatment groups in which dogs were , and the top end of this range was chosen to represent a 1× dose. Since then, the companion efficacy study revealed a starting dose of 0.022 mg kg −1 day −1 to be more appropriate for this specific formulation (Lewis et al., 2018) . Each treatment group contained four males and four females. Within a sex, dogs were stratified by weight into four blocks in descending order. Dogs from each block were then randomly assigned to each treatment group.
The dogs were randomly assigned to pens in order to neutralize any pen position effects.
Blinding was achieved through separation of functions. Personnel conducting clinical observations, measurements, and procedures remained blinded to which treatment group each dog belonged. The clinical and veterinary pathology laboratories were also blinded to the treatment group for a given animal relative to its specimens. Personnel involved with treatment calculations, preparations, and administration did not participate in clinical observations, measurements, and procedures.
| Dosing
Levothyroxine sodium tablets, USP (Thyro-Tabs ® Canine; LLOYD, Inc.) in strengths of 0.1-, 0.3-, 0.6-, or 0.8-mg, were used. The appropriate combination of tablets to provide 0.044, 0.132, or 0.220 mg/ kg, rounded down to the nearest 0.05 mg, was given orally once a day.
Doses were based on the most recent body weight and were adjusted, as necessary, if body weight changed during the study.
Dogs that vomited within 4 hr of dosing had the vomitus examined for the presence of test article. If tablets were present, the dog was redosed with the number and strength of the tablets identified. If the tablet strength could not be identified, the dog was redosed with one tablet of the largest strength of that dog's tablet combination. Dogs that vomited later than 4 hr after dosing were not redosed.
| Study variables and observations
Study variables were assessed twice during the acclimation phase and once during the following treatment weeks: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 22, 23, 25, and 26 qualitative evaluation for abnormalities in heart rate, rhythm, and cardiac conductivity). Blood was collected via jugular venipuncture, and urine was collected by cystocentesis, catheterization, or free-catch.
All procedures and sample collections were performed in the morning and 0-6 hr prior to dosing (18-24 hr after the previous dose) during the treatment weeks.
Dogs were observed twice daily during the acclimation phase and 3 times (prior to dosing, and at approximately 4 and 16 hr after dosing) during the treatment phase. Parameters evaluated included appearance of the eyes; characteristics of any urine, feces, or vomit in the cage; respiration character; description of behavior; and description of locomotion and musculature. Food consumption was measured daily (weight of food offered minus weight of food removed).
All dogs were euthanized by overdose of sodium pentobarbital given i.v. at the end of the study on either day 183 or 184. After euthanasia, they were exsanguinated prior to undergoing a complete gross necropsy. During necropsy, the wet weights of body organs were obtained. The thyroid and parathyroid glands were weighed together as a combined thyroid+parathyroid gland unit. Tissues for histopathology were preserved in 10% buffered formaldehyde except for eyes and testes, which were preserved in Zenker's solution. Tissues were prepared for processing by embedding in paraffin, sectioning, and staining with hematoxylin and eosin. Slides from all collected tissues in the 0×
and 10× groups and from tissues with gross abnormalities in the 2×
and 6× groups were evaluated.
| Pituitary-thyroid axis hormone assays
Blood collected into serum separator tubes was allowed to clot at room temperature for at least 30 min prior to being centrifuged at 1,100-1,300 g for 10 min. The tubes were then packed in insulated containers with refrigeration material and shipped the same day as collection to the analytical laboratory (Nucro-Technics, Scarborough, Ontario, Canada). Upon receipt the next day, the thyroid panel hormones (TT4, fT4, and TSH) were analyzed via automated chemiluminescent immunoassays utilizing an Immulite
Immunoassay System, which was manufactured at that time by Diagnostic Products Corporation. The assay kits for TT4 and TSH were specific for dogs, whereas the fT4 was a human-based assay kit. Please note that human-based kits that directly measure unbound thyroxine (without an initial dialysis step to separate the unbound thyroxine from the protein-bound thyroxine) tend to lead to skewed results because of the differences in the human serum matrices used for the standards and the canine serum matrices of the samples (Schachter et al., 2004) .
For performance qualification, blood was collected from three healthy Beagle dogs, with the serum subsequently analyzed (in duplicate) later that day and repeated on the following day. For TT4, the lower limit of quantitation (LLOQ) was 0.5 μg/dl, the interassay coefficient of variation (CV) was 2.7%-5.2%, and the intra-assay CV was 0%-6.4%. For fT4, the LLOQ was 0.3 ng/dl, the interassay CV was 2.5%-7.8%, and the intra-assay CV was 0%-11.5%. For TSH, the LLOQ was 0.03 ng/mL, the interassay CV was 0%-4.6%, and the intraassay CV was 0%. Variables evaluated once (i.e., organ weights) were evaluated by ANOVA using the MIXED procedure of SAS under the assumption of normality. The organ-to -body weight ratio was used in the analysis (g/kg basis) with the exception of pituitary weights, for which brain weight was used as the denominator (g/g basis). Data were logtransformed when necessary, prior to analysis to stabilize the residuals. Contrasts as described previously for repeated-measure variables were evaluated.
| Statistical evaluation
Results are presented as least-squares means and 95% confidence intervals where the assumption of normality could be supported; geometric means of the ls means and back-transformed 95% confidence intervals are provided where data were log-transformed prior to the analysis.
| RESULTS
Nominal doses were 0.044, 0.132, or 0.220 mg/kg given once every 24 hr in the 2×, 6×, and 10× groups, respectively. Actual daily doses were 0.0424 ± 0.0007 mg/kg for the 2× group; 0.1322 ± 0.0009 mg/kg for 6× group; and 0.2224 ± 0.0010 mg/kg for the 10× group.
No dog died or had a severe adverse reaction during the study. One dog in the 0× group was discovered to be pregnant shortly after the T A B L E 1 Geometric means (95% confidence intervals) or means ± SD (range) of physical examination findings with significant treatment group by gender interactions; n = 4 except the control females in which n = 3 Purina body condition score (1 = severely emaciated; 5 = ideal; 9 = profoundly obese)-arithmetic means ± SD (range) Female 3.8 ± 0.6 (3-5) 4.5 ± 0.6 (3-6) 3.9 ± 0.5 (3-5) 4.2 ± 0.8 (2-5) Male 4.7 ± 0.8 (3-6) 4.9 ± 0.5 (3-6) 4.9 ± 0.4 (4-6) 5.0 ± 0.6 (4-6) start of the study; her data were not used in any analyses. Increased activity, loose stools, feces with blood, and vomiting occurred sporadically in all groups, but more frequently in the treated groups.
A significant group by gender interaction (p < .05) was detected for heart rate ( Table 1) . Sinus tachycardia was sporadically observed on electrocardiograms in all groups, but more frequently in the treated groups. No other treatment-related electrocardiogram findings were observed. There was also a significant group by gender interaction (p < .05) for body condition score (Table 1) . However, there was no significant group effect on body weight.
The group by time interaction was statistically significant (p < .10) for respiratory rate. Within the time points (weeks 3, 7, 9, and 17)
that contained group effects, at least one of the levothyroxine-treated groups had significantly (p < .10) higher respiratory rate than that of the 0× group (Figure 1) .
The group by time interaction was also statistically significant The group by gender interaction was statistically significant (p < .05) for amylase, chloride, glucose, potassium, and phosphorous (Table 2 ). There was a significant (p < .10) group effect for total protein, albumin, globulin, albumin/globulin ratio, ALT, BUN, creatinine, sodium, and cholesterol (Table 3) . Values for albumin were lower in the 6× group, and values for total protein, globulins, BUN, creatinine, and cholesterol were lower in the 6× and 10× groups as compared to the control group. Sodium values were higher in the 10× group, and albumin-to-globulin ratio and ALT were higher in the 6× and 10× group as compared to the control group.
The group by gender interaction was statistically significant (p < .05) for mean corpuscular hemoglobin, mean corpuscular volume, basophils, monocytes, and "large unstained cells" (Table 2 ). There was a significant (p < .10) group effect for RBC and platelet count (Table 3) .
Values for RBC were higher in all treatment groups as compared to the 0× group. Platelet values were lower in the 2× and 6× groups than those in the 0× group.
The group by gender interaction was statistically significant (p < .05) for PT (Table 2 ). There was a significant (p < .10) group effect for APTT (Table 3) , with the time in the 6× group shorter than that in the 0× group.
The only urinalysis variable to have a statistically significant result was urine pH, which showed a group effect (p < .10) at Week 26. The urine pH was higher in the 10× group than the urine pH in the 0× group.
None of the gross necropsy observations were considered to be treatment-related; all were considered to be incidental or agonal. There was a significant (p < .05) group by gender interaction for kidney weight/body weight ratio ( Table 2 ). The group effect was significant (p < .10) for prostate weight/body weight ratio and thyroid+para-thyroid weight/body weight ratio (Table 3 ). The thyroid+parathyroid weight/body weight ratio in all treatment groups and the prostate weight/body weight ratio in the 2× and 6× groups were lower than the respective ratios in the 0× group. The pituitary weight/brain weight ratio in the 10× group was numerically lower than that of the 0× group (Table 3) ; however, it was not statistically significant (p > .10).
F I G U R E 1
Histologic findings included the lack of cortical atrophy associated with maturation-related thymus involution in any of the dogs in the 10× group. Among the groups that received levothyroxine sodium tablets, the fold increase in TT4 serum concentrations was less than the fold increase in dose. In general, for a fold increase in levothyroxine sodium dose, the TT4 serum concentrations increased by 54%-68%. This is similar to the findings of a large retrospective survey of diagnostic laboratory samples, in which dogs receiving >0.044 mg kg −1 day −1 had a mean TT4 serum concentration of 43.3 ng/ml, a 59% increase over the 27.3 ng/ml in dogs receiving <0.022 mg kg −1 day −1 (Nachreiner & Refsal, 1992) . A likely mechanism for the nonlinear relationship includes a greater than proportional increase in hepatic metabolism and biliary excretion with increasing dose.
| DISCUSSION
Serum albumin concentration was mildly decreased in the 6× group, with serum globulin and total protein concentrations mildly decreased in the 6× and 10× groups. In other species, decreased serum albumin was detected in hyperthyroid human patients (Buchanan, Koutras, Alexander, & Crooks, 1962; Kubota et al., 2008) and experimentally hyperthyroid rats (Nadkarni & Samuel, 1973) . Neither hyperthyroid humans (Buchanan et al., 1962) nor rats (Nadkarni & Samuel, 1973) had differences in serum globulins compared with euthyroid individuals. The mild decreases in serum albumin and globulin concentrations in the 6× and 10× groups are generally consistent with findings in humans and rats, and for these dogs were clinically not important.
Treatment with levothyroxine caused a dose-dependent decrease in BUN and serum creatinine concentrations. This is consistent with T A B L E 2 Geometric means or least-squares means (95% confidence intervals) of clinical chemistry analytes, hematology variables, coagulation times, and organ weights with significant treatment group by gender interactions in dogs receiving levothyroxine; n = 4 except the control females in which n = 3 what is observed in cats and humans with natural hyperthyroidism (den Hollander, Wulkan, Mantel, & Berghout, 2005; Williams, Peak, Brodbelt, Elliott, & Syme, 2010) . It is attributable to increased glomerular filtration rate, which is consistently associated with increased thyroid hormone concentrations across species (Gommeren et al., 2009; Mariani & Berns, 2012; Williams et al., 2010) .
Elevations in liver enzymes are a common finding in both humans (Kubota et al., 2008) and cats (Berent et al., 2007) with natural hyperthyroidism, and mild increases in mean ALT serum concentrations were detected in the 6× and 10× groups in this study. Various mechanisms may contribute to these elevations, including increases in oxygen consumption by the liver leading to tissue hypoxia (Youssef & Mullen, 2002) and alterations in mitochondrial function (Khemichian & Fong, 2011) . These elevations are generally reversible in humans and cats upon treatment of the hyperthyroidism, and are expected to have been reversible in these dogs if the levothyroxine treatment had been stopped. This expected reversibility is supported by the lack of histopathologic changes to the liver of these dogs.
Thyroid hormone is well known for its effects on serum cholesterol, with hypercholesterolemia a common finding in hypothyroid humans (Duntas & Brenta, 2012) and dogs (Scott-Moncrieff, 2010) and decreased serum cholesterol concentrations seen in hyperthyroid humans (Duntas & Brenta, 2012) and cats (Berent et al., 2007) .
Mechanisms for the influence of thyroid hormone on cholesterol include modulation of hepatic and extrahepatic low-density lipoprotein receptors and also the rate of hepatic clearance of cholesterol (Duntas & Brenta, 2012) . The decrease in mean serum cholesterol concentrations in the 6× and 10× groups is an expected finding.
There was a mild increase in mean serum sodium concentrations in the 10× group. Alterations in serum sodium are not listed as an expected finding in either human (DeGroot, 2000; Ford, Lim, Chisnall, & Pearce, 1989) or feline (Mooney, 2010) hyperthyroid patients. This lack of change in serum sodium concentrations in hyperthyroid patients is in contrast to the increased sodium reabsorption and decreased sodium excretion in various rodent models of hyperthyroidism (Katz & Lindheimer, 1973; Kinsella & Sacktor, 1985; Vargas, Atucha, Sabio, Quesada, & Garcia-Estan, 1994) . Why an increase in serum sodium concentrations was observed in the 10× group but not in human or feline hyperthyroid patients in unknown, but maybe related to species or thyroxine exposure differences. As the mean values for all groups were within reference ranges, the increase observed in this study is not clinically important.
T A B L E 3 Geometric means or least-squares means (95% confidence intervals) of clinical chemistry analytes, hematology variables, coagulation times, and organ weights by treatment group in dogs receiving levothyroxine; n = 8 unless stated Thyroid hormone status is well known to influence red blood cell indices (Bremner et al., 2012; Das, Mukherjee, Sarkar, Dash, & Rastogi, 1975; Scott-Moncrieff, 2010) . In the hypothyroid state, various mechanisms induce erythroid hypoplasia in the bone marrow leading to a nonregenerative anemia in approximately 25%-30% of human and canine patients. In the hyperthyroid state, these mechanisms are reversed leading to erythroid hyperplasia in the bone marrow (Das et al., 1975) . Although cats with hyperthyroidism often have increases in red blood cell indices (Broussard, Peterson, & Fox, 1995) , in human patients with hyperthyroidism, anemia is a common despite the bone marrow stimulation (Gianoukakis et al., 2009 ). The reasons for this are uncertain and may include underlying nutritional state, shortened red blood cell life span, ineffective erythropoiesis, and the duration and intensity of the hyperthyroidism leading to anemia of chronic disease (Das et al., 1975; Gianoukakis et al., 2009) . Regardless of the mechanisms leading to anemia in hyperthyroid human patients, none of them were apparently present in this population of healthy Beagle dogs, leading to the mild increases in RBC counts in the treatment groups receiving levothyroxine.
The effects of hyperthyroidism on platelets are different between natural and experimental models. Although thrombocytopenia is a common finding in humans with Graves' disease, the primary mechanism is generally attributed to autoimmune processes rather than increased thyroid hormone (DeGroot, 2000) . In cats with hyperthyroidism, there is a 20% increase in mean platelet size compared with euthyroid cats, but no difference in platelet numbers (Sullivan et al., 1993) . However, experimental hyperthyroidism decreases thrombocytopoiesis in mice (Sullivan & McDonald, 1992) and platelet survival in rats (Kurata, Nishioeda, Tsubakio, & Kitani, 1980) . These findings in experimental hyperthyroidism rodent models are consistent with the mild, clinically not important decrease in mean platelet numbers in the dogs receiving levothyroxine sodium in the study of this report.
Decreased APTT (Lippi et al., 2009 ) and predisposition to a hypercoagulable state (Franchini, Lippi, Manzato, Vescovi, & Targher, 2010) are reported in humans with natural hyperthyroidism. In healthy volunteers given 250 μg/day for 8 weeks, the resultant biochemical thyrotoxicosis induced increased expression of numerous procoagulant clotting factors and decreased fibrinolytic factors (Engelmann et al., 2015) . There were no changes in PT, APTT, and PIVKA (Proteins Induced by Vitamin K Absence or Antagonists) values in hyperthyroid cats before and after treatment with methimazole (Randolph et al., 2000) . The mild decrease in mean APTT in the 2× and 6× groups is consistent with the findings in humans. As the mean values were well within reference limits, the decrease in these dogs is clinically not important.
The effect of thyroid hormone on the prostate may be agedependent. In adults it appears to be stimulatory, as men with prostate cancer and benign prostatic hypertrophy have increased median serum concentrations of triiodothyronine (T3) as compared to men without prostatic disease; values for almost all patients were within reference ranges (Lehrer, Diamond, Stone, Droller, & Stock, 2002) .
Also, LNCaP cell cultures, a well-differentiated human prostatic cancer cell line, have increased growth when exposed to T3 (Zhang et al., 1999) . However, in juveniles, it appears to be inhibitory. Rats that were treated with T3 as juveniles had decreased prostate/body weight ratios (Talbert, 1962) , whereas those made transitorily hypothyroid by maternal treatment with 6-propyl-2-thiouracil during lactation had increased prostate/body weight ratios as adults (Cooke & Meisami, 1991) . Mean prostate/body weight ratios were decreased in all treated groups in the study of this report, indicating that thyroid hormone has an inhibitory effect on prostate growth when given to
Beagle dogs in the immediate postpubertal period.
Cortical thymic involution associated with maturation had occurred in six of seven group 0× dogs but not in any of the group 10× dogs. Thymic enlargement has been reported in adult humans with Graves' disease (Murakami et al., 1996) . Hypothesized mechanisms include thyroid hormone effects on thymic cortical tissue and stimulation of lymphoid tissue by TSH receptor autoantibodies (Dalla Costa, Mangano, & Betterle, 2014) . In rats, the effects of thyroid hormone on thymus size appear to be age-dependent, as those made hyperthyroid in the peripubertal period had increased thymus weights (Hassman et al., 1985) , whereas those made hyperthyroid as adults had decreased thymus weights (Johnson, Kamilaris, Calogero, Gold, & Chrousos, 2005) . This age effect is also seen in experimental hypothyroidism models, as rats thyroidectomized as neonates have decreased thymus weight/body weight ratios, whereas rats thyroidectomized at 60 days of age have thymus weight/body weight ratios similar to that of controls (Fabris, 1973) .
Of the variables with group by gender interactions, only two had overt dose-related trends: amylase serum activities increased in male dogs, and kidney weight/body weight ratio increased in female dogs. Alterations in amylase serum activities have not been reported for human (DeGroot, 2000) or feline (Broussard et al., 1995) hyperthyroid patients. In an experimental hyperthyroid rat model, proliferation of the pancreatic acinar cells was induced; however, serum amylase activities were actually lower than those in control rats (Ledda-Columbano, Perra, Pibiri, Molotzu, & Columbano, 2005) .
The reason for the differential response between male and female dogs in this study is unknown. As the mean amylase serum activities in the treated male dogs remained well within reference ranges, no dog developed clinical signs of pancreatitis, and no gross or histologic pancreatic lesions were noted, this finding is clinically not important.
Thyroid hormone appears to have stimulatory effect on kidney size in euthyroid individuals. Experimental hyperthyroidism in young adult rats increases the kidney weight/body weight ratio in both males (Kobori, Ichihara, Miyashita, Hayashi, & Saruta, 1998) and females (Katz & Lindheimer, 1973) . With respect to hypothyroid subjects, when evaluated after a sufficient duration of a euthyroid state, male rats with transient hypothyroidism as nurslings (Cooke & Meisami, 1991) and children with delayed treatment of congenital hypothyroidism (Bulbul, Cetinkaya, Eksioglu, Ozkasap, & Ginis, 2009 ) had kidney size/body weight ratios similar to those in control subjects. In the dogs of this study, levothyroxine treatment was associated with a dose-dependent increase in mean kidney weight/body weight in female dogs but not male dogs. The mechanisms for this differential effect are unknown.
In summary, doses of levothyroxine sodium given to healthy Beagle dogs at up to 10× the recommended starting dose for 6 months were well tolerated. As expected, TT4 and fT4 serum concentrations were elevated and TSH serum concentrations were decreased in treated an- 
